approach to heme malignancies lymphoma, multiple myeloma, acute leukemia and myeloid disorders dr....

Post on 18-Jan-2016

219 Views

Category:

Documents

0 Downloads

Preview:

Click to see full reader

TRANSCRIPT

Approach to Heme Malignancies

Lymphoma, Multiple Myeloma, Acute Leukemia and Myeloid Disorders

Dr. Michelle GeddesUniversity of Calgary and Tom Baker Cancer Centre

Nov 26, 2015

Objectives

• Organize the approach to working up possible hematologic malignancies

• Review presenting symptoms and signs in hematologic malignancies

• Outline the approach to therapy in different hematologic malignancies

• Review disease and treatment complications

Hematopoiesis

Lymphoid Malignancies

• Lymphoproliferative disorders

• B cells 80%, T cells 20% (terrible Ts)

• Chronic lymphocytic leukemia/small lymphocytic lymphoma

• Acute leukemia (B cell ALL, T cell ALL)

Hodgkins Lymphoma

– Classical HL– Nodular lymphocyte predominant HL

NonHodgkins Lymphomas

IndolentFollicular

Gastric MALT

Small lymphocytic lymphoma

Waldenstroms

Mantle cell lymphoma

Very AggressiveBurkitt

Lymphoblastic lymphoma

AggressiveDiffuse large B

cell lymphoma

Peripheral T Cell lymphoma

Double hit lymphoma

Case 1 – possible lymphoma

• 23 year old woman with cervical lymph node present for one month

• No infectious or B symptoms• Pruritis

On exam – Temp 38 C• 3 cm left anterior cervical LN, 4 cm left

supraclavicular lymph node

Labs - CBC – normal except WBC 15, neutrophils 13.2, eosinophils 1

• LDH elevated at 420

WHAT TESTS WOULD BE HELPFUL TO DETERMINE IF LYMPHOMA?

Making a Diagnosis…• BIOPSY the Node!

– Excisional biopsy>needle core>FNA

• Other bloodwork can be helpful:– CBC

– LDH

– ESR

– B2 microglobulin

– SPEP, quant immunoglobulins

• Bone marrow biopsy usually a staging procedure, not preferred as diagnostic test

A BIOPSY IS DONE…

Hodgkins lymphoma – Reed Sternberg cell

Hodgkins LymphomaB cell lymphoma with surrounding reactive T cells

NOW WHAT?STAGING LYMPHOMA

Lymph Node Regions

Staging (Ann Arbour System)

A – no B SymptomsB – presence of B Symptoms

Staging Hodgkins Lymphoma

• Physical Exam

• History of B symptoms

• CT neck, chest, abdomen and pelvis

• ? Bone marrow biopsy– Not necessary if less than stage IIB HYL as

unlikely to be involved (unlike NHL)• Hodgkins tends to have orderly spread

• PET scan– If limited stage disease, confirm with PET scan

PET scan

Treatment and Prognosis in Hodgkins Lymphoma

Treatment and prognosis of Limited Stage HL

• Favourable risk:– ABVD (adriamycin, bleomycin, vinblastine and

dacarbazine) x2 and 30 Gy involved field RT

• Unfavourable risk:– 4 cycles ABVD and 30 Gy IFRT– If B symptoms or bulky 6 cycles ABVD and

IFRT

Treatment and prognosis of advanced stage HL

• Good risk: ABVD x 6 +/- RT• If adverse risk factors:

– Escalated dose BEACOPP• Bleomycin, etoposide, adriamycin, cyclophosphamide,

vincristine, procarbazine, prednisone• More toxicities and infertility, MDS than ABVD; ABVD used in

those with few risk factors and elderly

– PET CT scan after therapy for residual disease

LOW GRADE NON-HODGKINS LYMPHOMAS

Case 2

• 64 year old man comes to see his GP with an enlarged lymph node in his groin

• Feels otherwise well, no B symptoms, no symptoms related to enlarged node

• Physical exam shows 2 cm LN in both axillae• CBC, LDH, SPEP normal

• A diagnostic procedure is performed…

Follicular Lymphoma

Follicular lymphoma

• 70% of all low grade lymphomas

• Older population, usually relatively asymptomatic at diagnosis with long history of waxing and waning lymph nodes– 75% with advanced stage

• Approximately 25% will transform at some time to an aggressive DLCL

Treatment of Follicular Lymphomas

• Generally watch and wait until symptomatic– Most treatment not curative– Exception – stage 1a or IIa nonbulky contiguous disease given RT for

cure

• Rituximab-Bendamustine is mainstay of first line therapy treatment indicated– fever, night sweats, weight loss, malaise, pain– Bulky or symptomatic lymphadenopathy– Impending organ compromise (compression, pleural/pericardial

effusions, ascites)– Cytopenias secondary to bone marrow infiltration

• Maintenance rituximab given q3 months for two years to prevent relapse and improve survival

Treatment of Follicular Lymphomas

Indolent Lymphomas Follicular Lymphoma

JCO 2009: 10;1607-14

Prognosis in Follicular Lymphoma

Specific indolent lymphomas have different treatment approach

• Mantle cell lymphoma – “indolent” lymphoma but relatively aggressive course with med survival 3-5y– R-CHOP then DHAP and autologous stem cell transplant

up front, maintenance Rituximab

• Gastric MALT, cutaneous indolent lymphomas• Splenic marginal zone lymphoma ‘

– Splenectomy

• Hairy cell leukemia – Splenomegaly and cytopenias– Cladrabine single 5-7 day course: 91% CR, OS at 4y 96%

AGGRESSIVE LYMPHOMAS

Case 3

• 54 year old patient presents with rapid development over 2-3 weeks of large left supraclavicular lymph node– Fevers, drenching sweats

– Appetite poor, weight loss10 lbs

• On exam: 5 cm left supraclavicular node– Cachexia

• A diagnostic procedure is performed…

Diffuse large B cell lymphoma

Diffuse large B cell lymphoma

• Most common type of lymphoma, incidence increases with age – 25% of all NHL

• Rapidly growing LNs, 30% have B symptoms• Advanced disease>localized disease• 30% bone marrow involvement, most high LDH• Can be extranodal disease

– 5-10% risk of CNS relapse

Treatment of DLCL

• Limited stage (I-IIa non-bulky)– If 0-1 IPI risk factors: R-CHOPx3 + IFRT– If 3 risk factors: R-CHOP x 6

• Advanced stage (stage III-IV, bulky, B symptoms)– R-CHOP x6– Add IFRT to sites of prior bulk

– PET scan after completion of therapy

Prognosis - International Prognotistic Index

T cell aggressive lymphomas

• Overall, prognosis is worse than B cell aggressive lymphomas

• Can present with T symptoms – terrible B symptoms, systemic symptoms

T cell lymphoma outcomes

Foss F M et al. Blood 2011;117:6756-6767

Treatment of Aggressive T cell Lymphomas

• CHOP– Overall, response in 50-70% with 5 year

disease-free survival around 30%– Compared to 50-60% for high risk DLBCL

• CHEOP – adding etoposide may improve 3y EFS (75% vs 51%) in patients 60y

• High risk fit patients often offered autologous transplantation in 1st complete remission

HIGHLY AGGRESSIVE LYMPHOMAS

Highly Aggressive Lymphomas

• B cell lymphomas∕leukemias– Burkitts lymphoma– Precursor B lymphoblastic leukemia ∕

lymphoma

• T cell lymphomas∕leukemias– Precursor T lymphoblastic

leukemia ∕ lymphoma

Highly Aggressive Lymphomas• Aggressive and prolonged inpatient protocols of combined 4

or 5 drug chemotherapy drugs– CNS prophylaxis and CNS-penetrating chemotherapy cranial

irradiation– 25% CNS relapse without treatment

• Overall survival 60% for T lymphoblastic lymphoma and Burkitts

• Pediatric-based very aggressive 2y protocols for ALL with 60% survival <age 60y– High risk patients alloBMT

Chronic Lymphocytic Leukemia

• Indolent lymphoproliferative disorders with median survival >15y overall

• Indications for treatment: – cytopenias, B symptoms, symptomatic or bulky

lymphadenopathy, consitutional symptoms

• Cytogenetics help determine prognosis and treatment options

Current CLL treatment

Overall Survival FCR vs BR

Eichhorst B, et al. ASH 2014:19

Bruton’s tyrosing kinase inhibitorIbrutinib : duration of response

OVERALL SURVIVAL

PROGRESSION-FREE SURVIVAL

0

20%

40%

60%

80%

100%

0 6 12 18 24 30 36 42

TN

R/R+ Censored

TN R/R

30-mo PFS 96.3% 68.4%

(95% CI)(76.5-99.5)

(56.1-77.9)

Median PFSNot

reachedNot

reached

0

20%

40%

60%

80%

100%

0 6 12 18 24 30 36

Months

TN

R/R

+ Censored

TN R/R

30-month OS

96.6% 79.9%

(95% CI)(77.9-99.5)

(69.0-87.3)

Median OSNot

reachedNot

reached

O’Brien S, et al. ASCO 2014; Oral/Abstract #7014

Idelalisib + rituximab

Furman et al NEJM 2014

Idelalisib + R improves overall survival

Furman et al NEJM 2014

Lymphoma Summary

• Divided into indolent, aggressive and highly aggressive malignancies

• Indolent lymphomas are not generally curable with chemo and less symptomatic– often diagnosed in advanced stage but with long survival

ie follicular– watch and wait, less intensive chemotherapy

• Aggressive lymphomas often curable with chemoradiation and are more symptomatic– more often diagnosed in early stages– chemotherapy IFRT given at diagnosis for cure

Case 4

• 60yo man presents with pathologic fracture of the humerus

• Fatigued, generally unwell for 6 months• Labs:

– Hb 90, remainder of CBC normal– Ca+ 2.7, creatinine 160, total protein 90

– What further investigations would you need to do?

Further investigations– SPEP shows IgG kappa monoclonal protein 32g, – B2 microglobulin 4.2, albumin 30, CRP high, Ig levels shows high

IgG – Serum free light chain index elevated at 326– Skeletal survey – multiple lytic bony lesions– Urine protein electropheresis and creatinine clearance

• Dipstick may not be positive (picks up albumin)

– A bone scan is not helpful!• Osteoclastic activity not osteoblastic in myeloma, does not light up on

bone scan

Diagnosis

CRAB (A)

• Calcium (>2.7)• Renal failure (>176)• Anemia (Hb<110)• Bony lesions• (Amyloidosis)

Cytogenetics and flow cytometry are sent for prognostic markers on bone marrow aspiration

Staging multiple myeloma

• Always comes out of an MGUS

• FISH for: t(14;16), t(4;14), deletion 17 (17p-) and del13q are prognostically important on bone marrow aspiration

Stage B2Microglobulin

Albumin Median Survival(months)

I <3.5 and 35 62

II ≥3.5 and <5.5 and/or <35 44

III ≥5.5 29

Treatment Approach in Myeloma

• Transplant eligible

• Non-transplant eligible

Treatment algorithm

Stem cell mobilization, autologous stem cell transplant then VRD x 2 cycles

Maintenance with lenalidomide until progression or bortezomib for 2 years

or

All patients IV bisphosphonatemonthly x2y

Prognosis post transplant in MM

Al-Mansour, et al. Adv Hematol. 2014; 2014: 652395.

Age >65y Age <65y

In non-transplant eligible, OS 60-70% at 4y

Myeloid disorders• Myelodysplastic syndromes• Myeloproliferative disorders

– Essential thrombocytosis, polycythemia vera, myelofibrosis– CML – tyrosine kinase inhibitors

• Acute myeloid leukemia– Intensive inpatient protocols with allogeneic transplantation

in high risk patients– Hypomethylating agents or low dose cytarabine in the

elderly

What raises a red flag that there is a myeloid disorder?

• Reasons to refer urgently: – Blasts – always!

– Nucleated red blood cells

– >1 unexplained cytopenia or a severe cytopenia

– Unexplained elevated blood counts:• Hb >185 in men or Hb>165 in women – check epo levels, jak2V617F

mutation if no obvious explanation for high Hb

• Thrombocytosis >450 persistent – look for reactive causes, iron deficiency

• Elevated white blood cells with left shift

Myelodysplastic Syndromes

• Clonal disorders of the bone marrow characterized by:– Low blood counts– Ineffective production of blood cells– Abnormal red cells, neutrophils and platelets– Increased risk of developing AML

Mr. G. Olfer

• 72 yo man with anemia for 4 years• Mildly low neutrophil count, no infections• Platelets normal, no bleeding• Now hemoglobin down to 60s, transfusion

dependent with 4u red cells transfused• Bone marrow biopsy shows MDS

• Refractory anemia with ringed sideroblasts

• What does this mean for him?

WHO 2008 Classification – A collection of myelodysplastic

syndromesRefractory Cytopenias with Unilineage Dysplasia (RCUD)

Refractory Anemia with Ring Sideroblasts (RARS)

Refractory Cytopenia with Multilineage Dysplasia

Refractory Anemia with Excess Blasts-1 (RAEB-1) (5-9% BM blasts)

Refractory Anemia with Excess Blasts-2 (RAEB-2) (10-19% BM blasts)

Myelodysplastic Syndrome - Unclassified

MDS Associated with Isolated del(5q)

< 20% blasts

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4 th edition. 2008.

Goals of Therapy

• Prolong survival

• Quality of life

• Improve symptoms

• Reduce transformation to acute leukemia

How do we decide if patients have lower risk or higher risk MDS?

• Blood counts

• Chromosome analysis

• Blast counts in bone marrow

• Age

• Type of MDS

IPSS-RRevised International Prognostic Scoring System

Greenberg P, Tuechler H, Schanz J, et al. Blood. 2012;120(12):2454

Very good = del(11q)Good = Normal, del(5q), del(12p), del(20q), double including del(5q)Intermediate = del(7q), 8, 19, i(17q), any other single or double independent clonesPoor = inv(3)/t(3q)/del(3q), double including 7/del(7q), complex: 3 abnormalitiesVery poor = Complex: 3 abnormalities

Syn
Dr. Zhu to review and make any necessary changes

Lower risk MDS• Growth factors i.e. erythropoietin

– increase red cells and reduce transfusions

• Transfusions, antibiotics, supportive care

• Iron chelation for iron overload from transfusions– Usually if ferritin>1000 and/or 20

transfusions red cells

Del 5q syndrome• 10-15% of MDS

– Anemia– Mild low white blood cells– Atypical megakaryocytes, normal to elevated

platelets– Transfusion dependence– Normal blast count

Extended survival with low frequency of AML transformation (10%)

Lenalidomide: RBC Transfusion Independence in Del(5q) MDS

Erythroid Response Rate (N=148) n (%) 95% CI

Transfusion independence* 99 (67) 59–74

≥50% decrease in no. transfusions 13 (9) 5–15

Total transfusion response 112 (76) 68–82

Transfusion Independence

Response Characteristics

Median Range

Time to response (wk) 46 1–49

Hgb increase† (g/dL) 54 11–114

N Eng J Med, 2006; 355: 1456

Mr. G. Olfer

• After 2 years, his platelets drop to 14 and he starts to have blasts in his peripheral blood

• Bone marrow biopsy shows refractory anemia with excess blasts-2• Blasts 11%, complex cytogenetics• Higher risk MDS

• What treatment options does he have?

Higher risk MDS

• Supportive care, transfusions

• Azacytidine Intermediate-2 and High risk MDS, low blast count AML– 7d subcutaneous injections every 4 weeks– Associated with improved survival, lower rate

of developing acute leukemia– Improved quality of life

Overall Survival: Azacitidine vs Conventional Care Regimen

Lancet Oncol 2009; 10:223-32.

p=0.0001p=0.0001

0 5 10 15 20 25 30 35 40

Time (months) from RandomizationTime (months) from Randomization

0.0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1.0

Pro

po

rtio

n S

urv

ivin

gP

rop

ort

ion

Su

rviv

ing

ConventionalCare

AZA

Survival Difference 9.4 monthsSurvival Difference 9.4 monthsOral azacytidine in developmentOral azacytidine in development

Between a rock and a hard place

Transplantation iscurrently the only curative therapyfor many hematologic malignancies

Median age at diagnosis is 65-70Toxicity of transplantation can be prohibitive

Role of Clinical Trials

Other supports available

• Home care• Wellspring• AAMAC• Leukemia and lymphoma society• Psychosocial services• Dieticians• Social work, home care, mobile lab

Questions?

Blood Moon

top related